A. Diamantopoulos

发表

PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

C. Lereun, C. Lohan, L. Sawyer, 2019, Value in Health.

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

T. Maher, C. Lereun, D. Esser, 2016, PharmacoEconomics.

PHC8 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT IN THE UK AND SPAIN

C. Piñol, M. Brosa, A. Diamantopoulos, 2008 .

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective

N. Sengupta, L. Kwong, A. Diamantopoulos, 2012, PharmacoEconomics.

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use

N. Schoof, T. Maher, C. Lereun, 2018, PharmacoEconomics - Open.

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

W. Wuyts, A. Gentilini, B. Bondue, 2020, PharmacoEconomics - Open.

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

C. Lereun, C. Lohan, L. Sawyer, 2019, BMJ open gastroenterology.

Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy

N. Wintfeld, W. Ricciardi, S. Capri, 2012, Journal of medical economics.

The Authors’ Reply

S. Mariz, A. Diamantopoulos, J. Bottomley, 2012, PharmacoEconomics.

Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement.

P. Wells, M. Kubin, A. Diamantopoulos, 2008 .

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain

M. Monreal, D. Imberti, M. Brosa, 2013, Thrombosis and Haemostasis.

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective

H. Mcdonald, P. Wells, J. Ananthapavan, 2012, Journal of medical economics.

Cost-effectiveness of rituximab (MabThera) compared with abatacept (Orencia) for the treatment of rheumatoid arthritis (RA) in the UK

A. Diamantopoulos, A. Kielhorn, G. Lewis, 2007 .

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.

D. Porter, A. Diamantopoulos, A. Kielhorn, 2008, Current medical research and opinion.

The Cancer Drugs Fund in Practice and Under the New Framework

K. Malottki, A. Diamantopoulos, C. Sabry-Grant, 2019, PharmacoEconomics.

Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System

I. Papageorgiou, K. Souliotis, A. Diamantopoulos, 2016 .

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada

H. Mcdonald, P. Wells, J. Ananthapavan, 2010, Thrombosis and Haemostasis.

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

N. Sengupta, L. Kwong, A. Diamantopoulos, 2011, Journal of medical economics.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement

N. Sengupta, P. Wells, C. Lereun, 2011, Journal of medical economics.

Economic value of insertable cardiac monitors in unexplained syncope in the United States

M. Reynolds, S. Bermingham, A. Diamantopoulos, 2021, Open Heart.

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK

Alexander Diamantopoulos, S. Mariz, A. Diamantopoulos, 2005, PharmacoEconomics.

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review

N. Schoof, T. Maher, E. Wright, 2018, PharmacoEconomics.

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

L. Fauchier, H. Diener, V. Thijs, 2016, International journal of stroke : official journal of the International Stroke Society.

The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe

S. Bermingham, A. Diamantopoulos, N. Bohm, 2021, PharmacoEconomics.

FRI0414 Tocilizumab in methotrexate-intolerant or contraindicated patients – a cost-utility model for scotland

C. Gibbons, A. Diamantopoulos, F. Dejonckheere, 2013 .

PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

C. Gibbons, A. Diamantopoulos, D. Harland, 2012 .

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

T. Huizinga, L. Sawyer, A. Finckh, 2014, PharmacoEconomics.

Abstract 14: Use of an Insertable Cardiac Monitor to Detect Atrial Fibrillation is Cost Effective in Patients with Cryptogenic Stroke

G. Lip, L. Fauchier, H. Diener, 2015 .

Integrating advanced technologies to uphold security of payment: Data flow diagram

Heap-Yih Chong, Alexander Diamantopoulos, H. Chong, 2020, Automation in Construction.

Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences

Marta Giulia Viola, Alexander Diamantopoulos, A. Diamantopoulos, 2019, Applied Health Economics and Health Policy.

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

D. Porter, A. Diamantopoulos, A. Kielhorn, 2008 .

Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

I. Björholt, A. Diamantopoulos, M. Lees, 2011, Expert review of pharmacoeconomics & outcomes research.

Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the UK

M. Elkind, K. Witte, M. Reynolds, 2019, Open Heart.

Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysis.

B. Gaynes, C. Lereun, A. Diamantopoulos, 2019, Comprehensive psychiatry.

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

L. Mantovani, J. Bernier, P. Schöffski, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PMH36 A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST CURRENT STIMULANT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY

M. Happich, A. Diamantopoulos, S. Cottrell, 2007 .

Validity of Cost and Utility Results?

L. Sawyer, A. Diamantopoulos, S. Ogale, 2012, PharmacoEconomics (Auckland).

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

C. Lereun, C. Lohan, L. Sawyer, 2019, BMJ open gastroenterology.

Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective

N. Sengupta, L. Kwong, A. Diamantopoulos, 2012, PharmacoEconomics.

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework

T. Maher, A. Diamantopoulos, K. Rohr, 2021, Advances in Therapy.